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Article Corrected
Tasocitinib. Drugs R D 2010; 10 (4): 271-284
Corrections Made
The drug name has changed and should be referred to as ‘tofacitinib’ throughout the document.
Page 271: In the abstract, the second sentence, which previously read:
‘‘Tasocitinib specifically inhibits Janus activated kinase 3 (JAK3), which hasy’’
has now been corrected as follows:
‘‘Tofacitinib inhibits Janus activated kinase 3 (JAK3), which hasy’’
Page 272: In the second paragraph of section 1.1.4, the third sentence, which previously read:
‘‘The trial enrolled 249 de novo renal allograft recipientsy’’
has now been corrected as follows:
‘‘The trial enrolled 61 de novo renal allograft recipientsy’’
Page 272: In the second paragraph of section 1.1.4, the fifth sentence, which previously read:
‘‘Enrollment of 54 patients was completedy’’
has now been corrected as follows:
‘‘Enrollment of 45 patients was completedy’’
Page 272: In the third paragraph of section 1.1.5, the first sentence, which previously read:
‘‘ycompare the efficacy of tasocitinib with methotrexatey’’
has now been corrected as follows:
‘‘...compare the efficacy of two doses of tofacitinib with methotrexatey’’
Page 273: In the left column, third paragraph, the first sentence, which previously read:
‘‘yefficacy and safety of tasocitinib in 2500 patientsy
has now been corrected as follows:
‘‘...efficacy and safety of tofacitinib in 4000 patients...’’
Page 274: In the first paragraph of section 2.2.2, the first sentence, which previously read:
‘‘ywere low in the phase II/III ORAL Solo trialy’’
has now been corrected as follows:
‘‘...were low in the phase III ORAL Solo trialy’’
Page 275: In the left column, second paragraph, the first sentence, which previously read:
‘‘No new safety signals have emerged in the ongoing ORAL Sequel phase II/III 2-year extension
studyy’’
has now been corrected as follows:
‘‘No new safety signals have emerged over 2 years in the ongoing ORAL Sequel phase II/III
extension studyy’’
Page 275: In the right column, second paragraph, the first sentence, which previously read:
‘‘In a 1-year extension study that included patientsy’’
has now been corrected as follows:
‘‘After 1 year of an extension study that included patientsy’’
Page 275: In the right column, third paragraph, the first sentence, which previously read:
‘‘...at dosages of 2–20mg/day,y’’
has now been corrected as follows:
‘‘...at doses of 1–10mg twice daily,y’’
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Page 277: In the fifth paragraph of section 2.4.1, the first sentence, which previously read:
‘‘Cynomolgus monkeys receiving tasocitinib had a significantly longery’’
has now been corrected as follows:
‘‘Cynomolgus monkeys receiving tofacitinib following bilateral nephrectomy and allogeneic renal
transplant had a significantly longery’’
Page 278: In the right column, lines 1 and 2, which previously read:
‘‘ytwice daily groups at 6 months, compared with the placebo group.’’
has now been corrected as follows:
‘‘ytwice daily groups at 3 months, compared with the placebo group.’’
Page 281: In the left column, second paragraph, which previously read:
‘‘ysignificantly improved pain and physical function at 6 weeksy’’
has now been corrected as follows:
‘‘...significantly improved ACR response rates at 6 weeksy’’
Page 281: In the right column, the second paragraph starting with ‘‘One-year efficacy datay’’ should
be deleted entirely.
Page 281: In the right column, third paragraph, the first sentence, which previously read:
‘‘Tasocitinib, at dosages of 2–20mg/day, was effectivey’’
has now been corrected as follows:
‘‘Tofacitinib, at doses of 1–10mg twice daily, was effectivey’’
Note
All online versions of this article have been updated to reflect these corrections.
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Page 157: Column 2, line 12 should read ‘‘y a Japan Coma Scale score of 20 or more, history of
neurologic dysfunctiony’’
Page 159: Table I, in the ‘Long-term edaravone’ column, the ‘Severe leg weakness [n (%)]’ values
should read ‘‘10 (50.0)’’
Page 160: Column 2, line 2 should read ‘‘... in the paretic leg and MWS (r = -0.87; p < 0.001)y’’
Page 161: Figure 1 should be:
Page 161: In the legend of figure 1, line 3 should read ‘‘...in the grade of the paralyzed leg atrophy
(r =-0.87; p < 0.001)...’’
[Naritomi H, Moriwaki H, Metoki N, et al. Effects of edaravone on muscle atrophy and locomotor
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